The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Like virtually all age‐related chronic diseases, late‐onset Alzheimer's disease (AD) develops over an extended preclinical period and is associated with modifiable lifestyle and environmental factors. We hypothesize that multimodal interventions that address many risk factors simultaneously and are individually tailored to patients may help reduce AD risk. We describe a novel clinical methodology used to evaluate and treat patients at two Alzheimer's Prevention Clinics. The framework applies evidence‐based principles of clinical precision medicine to tailor individualized recommendations, follow patients longitudinally to continually refine the interventions, and evaluate N‐of‐1 effectiveness (trial registered at ClinicalTrials.gov NCT03687710). Prior preliminary results suggest that the clinical practice of AD risk reduction is feasible, with measurable improvements in cognition and biomarkers of AD risk. We propose using these early findings as a foundation to evaluate the comparative effectiveness of personalized risk management within an international network of clinician researchers in a cohort study possibly leading to a randomized controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072 · cited 3×
“Accumulating evidence suggests that modifiable risk factors for AD can be addressed in an effort to delay onset [20,61,62].”
BackgroundNgandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689 · cited 1×
“Accumulating evidence suggests that modifiable risk factors for AD can be addressed in an effort to delay onset [20,61,62].”
BackgroundBig Data and Machine Learning in Health Care
Beam, A. L., & Kohane, I. S. (2018) · JAMA · doi:10.1001/jama.2017.18391 · Cited by 2,506 · cited 2×
“of clinical care augmented by predictive analytics will most likely fall within the continuum of entirely human-guided versus fully machine-guided patient care [64].”
BackgroundPotential for primary prevention of Alzheimer's disease: an analysis of population-based data
Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K., & Brayne, C. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70136-x · Cited by 2,466
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“Evolving evidence has helped define target age groups for implementing risk reduction interventions for AD [5,6].”
BackgroundAndrieu, S., Guyonnet, S., Coley, N., Cantet, C., Bonnefoy, M., Bordes, S., Bories, L., Cufi, M.-N., Dantoine, T., Dartigues, J.-F., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30040-6 · Cited by 838
Mediterranean Diet and Mild Cognitive Impairment
Scarmeas, N., Stern, Y., Mayeux, R., Manly, J. J., Schupf, N., & Luchsinger, J. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.536 · Cited by 757
Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition
Gottesman, R. F., Schneider, A. L. C., Zhou, Y., Coresh, J., Green, E., Gupta, N., Knopman, D. S., Mintz, A., Rahmim, A., Sharrett, A. R., et al. (2017) · JAMA · doi:10.1001/jama.2017.3090 · Cited by 650 · cited 1×
“Several known modifiable factors are associated with increased risk for AD development, such as hypertension and physical inactivity [18,19].”
Background
Cited by
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.23 · Cited by 744
“Following AD diagnosis, a comprehensive approach toward clinical care can be individualized based on the patient’s specific AD risk factors (20, 21).”
Self-citationAlzheimer’s Disease – Why We Need Early Diagnosis
Rasmussen, J., & Langerman, H. (2019) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s228939 · Cited by 501
“8,18 There is a greater likelihood of progression in those with more than one of these risk factors.”
InfluentialPike, K. E., Cavuoto, M. G., Li, L., Wright, B. J., & Kinsella, G. J. (2022) · Neuropsychology Review · doi:10.1007/s11065-021-09522-3 · Cited by 259
Rahman, A., Jackson, H., Hristov, H., Isaacson, R. S., Saif, N., Shetty, T., Etingin, O., Henchcliffe, C., Brinton, R. D., & Mosconi, L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00315 · Cited by 187
“In order to address the growing AD epidemic, the field is shifting toward early detection and primary and secondary prevention efforts (Isaacson et al., 2018).”
BackgroundSelf-citationUsing the Biopsychosocial Model to Guide Patient-Centered Neurological Treatments
Saxena, A., Paredes-Echeverri, S., Michaelis, R., Popkirov, S., & Perez, D. L. (2022) · Seminars in Neurology · doi:10.1055/s-0041-1742145 · Cited by 53
Metadata
- Authors
- Isaacson, R. S., Ganzer, C. A., Hristov, H., Hackett, K., Caesar, E., Cohen, R., Kachko, R., Meléndez‐Cabrero, J., Rahman, A., Scheyer, O., Hwang, M. J., Berkowitz, C., Hendrix, S., Mureb, M., Schelke, M. W., Mosconi, L., Seifan, A., & Krikorian, R.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2018-11-13
- Volume
- 14
- Issue
- 12
- Pages
- 1663-1673
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2900627486
- Cited by
- 103
- References
- 23
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach. https://app.cochat.ai/papers/10.1016/j.jalz.2018.08.004
- The paper
- Isaacson, R. S., Ganzer, C. A., Hristov, H., Hackett, K., Caesar, E., Cohen, R., Kachko, R., Meléndez‐Cabrero, J., Rahman, A., Scheyer, O., Hwang, M. J., Berkowitz, C., Hendrix, S., Mureb, M., Schelke, M. W., Mosconi, L., Seifan, A., & Krikorian, R. (2018). The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2018.08.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.